Table 1. The baseline characteristics of included studies.
| First author, year | Country | Sample source | No. of HCC | Treatment | MDSC definition | Measure method | Cut-off | Outcome |
|---|---|---|---|---|---|---|---|---|
| Elwan 2018 | Egypt | PB | 20 | NR | Lin-HLA-DR-CD11b+CD33+ | FACS | NR | NR |
| Zhou, 2018 | China | PB, Tumor tissue |
PB:26 Tissue:102 |
NR | PB:HLA-DR-CD11b+CD33+ Tissue:CD11b/CD33/CCRK |
PB:FACS Tissue:qRT-PCR |
Median | OS, RFS |
| Li, 2017 | China | PB | 55 | NR | HLA-DR-/lowCD11b+CD33+ | FACS | NR | NR |
| Deng, 2017 | China | Tumor tissue | 78 | NR | CD11b+ | IHC | Median | OS |
| Gao, 2017 | China | PB | 183 | Surgery | HLA-DR-/lowCD14+ | FACS | Median | OS,TTR |
| Iwata, 2016 | Japan | PB | 122 | RFA and TACE | PDL1+HLA-DR-/lowCD11b+CD33+CD14+ | FACS | Median | NR |
| Kalathil, 2016 | USA | PB | 19 | Sorafenib | CD11b+CD33+ | FACS | NR | NR |
| Mizukoshi, 2016 | Japan | PB | 36 | Chemotherapy | HLA-DR-/lowCD14+ | FACS | Median | NR |
| Wang, 2016 | China | PB | 92 | Radiotherapy | HLA-DR-/lowCD14+ | FACS | Average+2SD | OS |
| Arihara, 2013 | Japan | PB | 123 | NR | HLA-DR-/lowCD14+ | FACS | Average+2SD | OS, RFS |
| Kalathil, 2013 | USA | PB | 23 | NR | HLA-DR-CD11b+CD33+CD14- | FACS | NR | NR |
| Mizukoshi, 2013 | Japan | PB | 12 | RFA | HLA-DR-/lowCD14+ | FACS | NR | NR |
| Hoechst, 2008 | Germany | PB | 111 | NR | HLA-DR-/lowCD14+ | FACS | NR | NR |
Abbreviations: NR, not reported; PB, peripheral blood; IHC, immunohistochemistry; RFA, radiofrequency ablation; TACE, trans arterial chemo-embolization; FACS, fluorescence-activated cell sorting; OS, overall survival; RFS, recurrence-free survival; TTR, Time to recurrence